Leading researchers believe a viable HIV vaccine could emerge by 2021, marking a potential turning point. Full recoveries from AIDS remain exceptionally rare, underscoring the urgency of these advancements.
According to an NBC News report from December 1, 2019, the HVTN 702 vaccine stands out as the leading candidate. As the most advanced trial in progress, it builds on the RV144 vaccine, which demonstrated modest 30% efficacy in reducing infections. Experts at the National Institute of Allergy and Infectious Diseases (NIAID) project HVTN 702 could achieve up to 50% effectiveness. Initiated in South Africa in 2016 following RV144's limitations, this trial represents a refined approach backed by rigorous science.
The San Francisco Department of Public Health echoes this optimism, noting three promising vaccines under evaluation: HVTN 702, Imbokodo, and Mosaico. While Imbokodo and Mosaico lag behind, they share similar regimens requiring six injections and are advancing through key phases.
Imbokodo is in phase 2, and Mosaico in phase 3. Early-phase results are critical; positive outcomes pave the way for large-scale efficacy studies. Though past trials have faltered, these developments are progressing swiftly. Researchers remain cautiously optimistic, with successful results potentially accelerating even more effective vaccines down the line.
A November 15, 2019, WHO report highlighted that 38 million people lived with HIV in 2018, with over 32 million deaths recorded to date. In 2015, Bill Gates predicted an AIDS cure by 2030, fueling long-term hope.
Related Articles:
